Open AccessThe Role of epigenetic modifications of DNA and histones in the treatment of oncohematological diseases
Author(s) -
Dmitriy Karpenko,
Nataliya Petinati,
Nina Drize,
Alexey Bigildeev
Publication year - 2021
Publication title -
gematologiâ i transfuziologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 5
eISSN - 2411-3042
pISSN - 0234-5730
DOI - 10.35754/0234-5730-2021-66-2-263-279
Subject(s) - epigenetics , histone , epigenetic therapy , histone deacetylase , dna methylation , carcinogenesis , biology , cancer epigenetics , acetylation , cancer research , epigenesis , computational biology , bioinformatics , genetics , cancer , dna , histone methyltransferase , gene , gene expression
. Current knowledge of tumour biology attests a dual genetic and epigenetic nature of cancer cell abnormalities. Tumour epigenetics research provided insights into the key pathways mediating oncogenesis and facilitated novel epigenetic therapies. Aim — an overview of intricate involvement of epigenetic change in haematological morbidity and current therapeutic approaches to target the related mechanisms. Main findings . We review the best known epigenetic marks in tumour cells, e.g. DNA cytosine methylation, methylation and acetylation of histone proteins, the underlying enzymatic machinery and its role in oncogenesis. The epigenetic profile-changing drugs are described, including DNA hypomethylating agents, histone deacetylase and methylase inhibitors. A particular focus is made on substances currently approved in haematological therapy or undergoing clinical trial phases for future clinical availability.